BiobankCell BiologyBio-Analysis

Principles of Biobanking

Metabolic Disease Biobank

There has been growing recognition, by regulatory bodies, that in order to fully capitalize on the advances in genomics, and to accelerate the development of personalized diagnostics and therapeutics, high-quality biobanks are required. High-quality refers to (i) biological quality of obtained samples, (ii) quality of associated clinical data, and (iii) the ethical and legal status under which samples are obtained. Historically, many biobanks were created on an ad-hoc basis by interested researchers willing to fulfill a specific set of objectives and tissue collection. Storage conditions, Information Management Systems, Ethical and Legal policies varied depending on the purpose of the biobank. Many specimens are of limited use for modern research due to age of samples, method of fixation, absence of associated patient information and poor quality of tissue specimens. Similarly, the donor consent may be required to perform certain types of research on samples, but in some biobanks obtaining such information can be impossible as traceability was never assured. Furthermore, the extent of information collected with specimens can be limited and variable. The heterogeneity of biobanks limits the ability to pool and compare bio-specimens.

One of the greatest challenges facing biobanking is the fact that small variations in bio-specimen acquisition, handling, processing and storage can produce variations in the quality and the reproducibility of results. The standard operating procedures used by the bio-specimen collection network enables to pool samples acquired, handled, processed and stored in the same manner. Researchers will be able to measure genuine biological differences rather than sample-to-sample variability.

  • CellMade created a bio-specimen collection network with standardized procedures for acquisition, preservation and storage of clinically annotated samples
  • Best Practices for Bio-specimen Resources have been implemented including a sophisticated security and information technology infrastructure

The biobank contains demographic data, diagnosis, treatment and follow-up of patients.  Our biobank also develops collections of matched, healthy samples. It is important to provide matched healthy control samples as the development of biomarkers depends on the diagnosis of disease knowing the scope of normal variation versus pathological deviation. Indeed, by understanding what is “normal”, it may be possible to identify biomarkers that can be used for early detection of inflammatory disease. Establishing a normal profile can be extremely complex. While obtaining blood samples from healthy patients may be relatively straightforward, the prospective and invasive collection of healthy tissue for research is far much challenging.

The  biobank, is likely to deliver a first wave of personalized diagnosis and therapies and services through a greater understanding if individual risk profiles and variability to drug response as well as rates and occurrence of drug toxicity.  The creation of the Biobank with collections of disease and matched healthy control samples leads to a better understanding of the scope of normal human variation which makes it possible to identify biomarkers that can be used for early detection of inflammatory disease. The main advantage of working with the disease-focused biobank is gaining access to defined disease and healthy control samples enabling rapid development of new biomarkers.

CellMade developed its Biobanking activities to create primary cell models, 3D and co-culture models, cell-based assays for target discovery and validation, screening of novel compounds, modelling of pharmacokinetic effects of new therapies as well as discovery and validation of biomarkers. The different products and services published on this website are all based upon the use of our Inflammation disease-focused biobank.

CellMade Disease-focused biobank – Valuable Biological Ressources for Discovery and Validation of Biomarkers in the field of Metabolic Diseases

  • Healthy ("Normal") Samples
  • Disease-focused Samples
    • Obesity (+/- NAFLD-NASH) – Diabetes Type II
    • Obesity (+/- NAFLD-NASH) – Cardiovascular Disease
    • Obesity (+/- NAFLD-NASH) – Chronic Obstructive Pulmonary Disease

 

Contact us

CellMade Laboratoire

20, impasse des Sources
73310 RUFFIEUX

T : 04 57 34 53 02